CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 35.8% in February

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large growth in short interest in February. As of February 13th, there was short interest totaling 41,351 shares, a growth of 35.8% from the January 29th total of 30,452 shares. Based on an average trading volume of 25,502 shares, the short-interest ratio is currently 1.6 days. Approximately 6.7% of the company’s stock are sold short. Approximately 6.7% of the company’s stock are sold short. Based on an average trading volume of 25,502 shares, the short-interest ratio is currently 1.6 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $20.00.

CNS Pharmaceuticals Stock Performance

NASDAQ CNSP traded up $0.05 during trading hours on Wednesday, hitting $3.09. The company had a trading volume of 6,322 shares, compared to its average volume of 44,947. The business has a 50 day moving average of $5.01 and a 200-day moving average of $6.63. The company has a market cap of $1.92 million, a PE ratio of -0.10 and a beta of 2.70. CNS Pharmaceuticals has a 1-year low of $2.94 and a 1-year high of $55.20.

Institutional Investors Weigh In On CNS Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new stake in shares of CNS Pharmaceuticals in the second quarter valued at approximately $335,000. Ikarian Capital LLC purchased a new position in CNS Pharmaceuticals during the 4th quarter worth $241,000. Finally, Boothbay Fund Management LLC acquired a new position in CNS Pharmaceuticals in the fourth quarter valued at $71,000. Hedge funds and other institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.